Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Cash from Operations (2018 - 2025)

Historic Cash from Operations for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $2.9 million.

  • Exagen's Cash from Operations rose 23529.41% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.2 million, marking a year-over-year decrease of 9363.31%. This contributed to the annual value of -$13.3 million for FY2024, which is 818.01% up from last year.
  • Exagen's Cash from Operations amounted to $2.9 million in Q3 2025, which was up 23529.41% from -$2.9 million recorded in Q2 2025.
  • In the past 5 years, Exagen's Cash from Operations ranged from a high of $8.3 million in Q4 2023 and a low of -$11.2 million during Q2 2022
  • Its 5-year average for Cash from Operations is -$4.8 million, with a median of -$5.5 million in 2021.
  • Per our database at Business Quant, Exagen's Cash from Operations plummeted by 15657.89% in 2021 and then surged by 24560.52% in 2023.
  • Exagen's Cash from Operations (Quarter) stood at -$6.0 million in 2021, then increased by 5.18% to -$5.7 million in 2022, then skyrocketed by 245.61% to $8.3 million in 2023, then tumbled by 95.65% to $363000.0 in 2024, then surged by 711.02% to $2.9 million in 2025.
  • Its Cash from Operations stands at $2.9 million for Q3 2025, versus -$2.9 million for Q2 2025 and -$10.7 million for Q1 2025.